MENU
+Compare
VRNA
Stock ticker: NASDAQ
AS OF
Aug 7 closing price
Price
$105.40
Change
+$0.01 (+0.01%)
Capitalization
9.08B

VRNA stock forecast, quote, news & analysis

Verona Pharma PLC is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs... Show more

VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. VRNA showed earnings on April 29, 2025. You can read more about the earnings report here.
Interact to see
Advertisement
A.I.Advisor
a Summary for VRNA with price predictions
Aug 07, 2025

VRNA in -0.08% downward trend, falling for three consecutive days on August 06, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where VRNA declined for three days, in of 313 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 21 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The Moving Average Convergence Divergence Histogram (MACD) for VRNA turned negative on July 23, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .

VRNA broke above its upper Bollinger Band on August 04, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on July 09, 2025. You may want to consider a long position or call options on VRNA as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VRNA advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 224 cases where VRNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VRNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (32.680) is normal, around the industry mean (18.130). P/E Ratio (0.000) is within average values for comparable stocks, (57.859). VRNA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.470). Dividend Yield (0.000) settles around the average of (0.047) among similar stocks. P/S Ratio (39.841) is also within normal values, averaging (276.117).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Moderna (NASDAQ:MRNA), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), BioCryst Pharmaceuticals (NASDAQ:BCRX), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.29B. The market cap for tickers in the group ranges from 58 to 199.59B. NONOF holds the highest valuation in this group at 199.59B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 1%. For the same Industry, the average monthly price growth was 8%, and the average quarterly price growth was 12%. ACXP experienced the highest price growth at 1,326%, while BIVI experienced the biggest fall at -52%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -16%. For the same stocks of the Industry, the average monthly volume growth was -17% and the average quarterly volume growth was 131%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 57
SMR Rating: 93
Profit Risk Rating: 95
Seasonality Score: -13 (-100 ... +100)
View a ticker or compare two or three
VRNA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a r&d company for the treatment of allergic rhinitis and other chronic respiratory diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
3 More London Riverside
Phone
+44 2032834200
Employees
79
Web
https://www.veronapharma.com